<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01209650</url>
  </required_header>
  <id_info>
    <org_study_id>1200.47</org_study_id>
    <nct_id>NCT01209650</nct_id>
  </id_info>
  <brief_title>LUX Lung Special Access Scheme Australia Named Patient Use (NPU)</brief_title>
  <official_title>Expanded Access Program BIBW 2992 for Non Small Cell Lung Cancer ( NSCLC) Last Line Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      The program will provide early access to the investigational drug BIBW 2992 to treat patients&#xD;
      with advanced NSCLC who have failed at least 12 weeks on erlotinib or gefitinib.&#xD;
&#xD;
      The Compassionate Use Programme will also provide additional safety and efficacy information&#xD;
      on BIBW 2992 use.&#xD;
&#xD;
      Named Patient Use (NPU)&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Approved for marketing</overall_status>
  <study_type>Expanded Access</study_type>
  <has_expanded_access>No</has_expanded_access>
  <condition>Carcinoma, Non-Small-Cell Lung</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BIBW 2992</intervention_name>
    <description>tablets</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  Patients with pathologic confirmation of adenocarcinoma of the lung Stage IIIB with&#xD;
             pleural effusion or Stage IV&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Brain metastases which are symptomatic; patients with treated, asymptomatic brain&#xD;
             metastases are eligible with stable brain disease for at least four 4 weeks without&#xD;
             the requirement for steroids or anti epileptic therapy&#xD;
&#xD;
          -  Significant or recent acute gastrointestinal disorders with diarrhea as a major&#xD;
             symptom as judged by the investigator.&#xD;
&#xD;
          -  Patients who have any other life-threatening illness or organ system dysfunction,&#xD;
             which in the opinion of the investigator, would either compromise patient safety or&#xD;
             interfere with the evaluation of the safety of the test drug&#xD;
&#xD;
          -  History of cardiac disease that is clinically significant, as judged by the&#xD;
             investigator or uncontrolled cardiac disease (including congestive heart failure,&#xD;
             angina, myocardial infarction, arrhythmia, including New York Heart Association (NYHA)&#xD;
             functional classification of 3)&#xD;
&#xD;
          -  Cardiac left ventricular function with resting ejection fraction of less than 50%&#xD;
&#xD;
          -  Bilirubin 1.5 mg / dl (26 mol / L, SI unit equivalent)&#xD;
&#xD;
          -  Aspartate amino transferase (AST) or alanine amino transferase (ALT) three times the&#xD;
             upper limit of normal (if related to liver metastases five times the upper limit of&#xD;
             normal)&#xD;
&#xD;
          -  Serum creatinine 1.5 times of the upper normal limit or calculated/measured creatine&#xD;
             clearance 45ml/min&#xD;
&#xD;
          -  Women of child-bearing potential or men who are able to father a child unwilling to&#xD;
             use a medically acceptable method of contraception during the trial&#xD;
&#xD;
          -  Pregnancy or breast feeding&#xD;
&#xD;
          -  Patients unable to comply with the protocol&#xD;
&#xD;
          -  Patients with known HIV, active hepatitis B or active hepatitis C&#xD;
&#xD;
          -  Pre-existing Interstitial Lung Disease (ILD)&#xD;
&#xD;
          -  Requirement for treatment with any of the prohibited concomitant medications listed in&#xD;
             Section 4.2.2.1.&#xD;
&#xD;
          -  Patients already pre-treated with BIBW 2992&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>1200.47.1 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>North Ryde</city>
        <state>New South Wales</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <study_first_submitted>September 24, 2010</study_first_submitted>
  <study_first_submitted_qc>September 24, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 27, 2010</study_first_posted>
  <last_update_submitted>November 9, 2016</last_update_submitted>
  <last_update_submitted_qc>November 9, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 10, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Afatinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

